• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to "Embracing imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19".

作者信息

Wu Xiaoming, Shi Jialan

机构信息

Department of Hematology, The First Hospital, Harbin Medical University, Harbin, 150001, China.

Department of Research, VA Boston Healthcare System, Harvard Medical School, Boston, MA, 02215, USA.

出版信息

Angiogenesis. 2023 Nov;26(4):485-486. doi: 10.1007/s10456-023-09894-5. Epub 2023 Sep 2.

DOI:10.1007/s10456-023-09894-5
PMID:37659007
Abstract
摘要

相似文献

1
Reply to "Embracing imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19".对《接受伊马替尼：保护新冠病毒肺炎患者内皮屏障的新方法》的回复
Angiogenesis. 2023 Nov;26(4):485-486. doi: 10.1007/s10456-023-09894-5. Epub 2023 Sep 2.
2
Embracing Imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19.采用伊马替尼：保护 COVID-19 患者内皮屏障的新方法。
Angiogenesis. 2023 Nov;26(4):481-483. doi: 10.1007/s10456-023-09889-2. Epub 2023 Aug 2.
3
Identification of differentially expressed proteins in imatinib mesylate-resistant chronic myelogenous cells.甲磺酸伊马替尼耐药慢性粒细胞中差异表达蛋白的鉴定
J Biochem Mol Biol. 2005 Nov 30;38(6):725-38. doi: 10.5483/bmbrep.2005.38.6.725.
4
Imatinib mesylate in the treatment of gastrointestinal stromal tumour.甲磺酸伊马替尼治疗胃肠道间质瘤
Expert Opin Pharmacother. 2005 Jan;6(1):105-13. doi: 10.1517/14656566.6.1.105.
5
Are off-target effects of imatinib the key to improving beta-cell function in diabetes?伊马替尼的脱靶效应是否是改善糖尿病患者β细胞功能的关键？
Ups J Med Sci. 2022 Sep 14;127. doi: 10.48101/ujms.v127.8841. eCollection 2022.
6
Novel mechanisms for maintaining endothelial barrier function in sepsis.脓毒症中维持内皮屏障功能的新机制。
Circulation. 2012 Dec 4;126(23):2677-9. doi: 10.1161/CIRCULATIONAHA.112.146100.
7
Combined Therapy of Gastrointestinal Stromal Tumors.胃肠道间质瘤的联合治疗
Surg Oncol Clin N Am. 2016 Oct;25(4):735-59. doi: 10.1016/j.soc.2016.05.006. Epub 2016 Aug 3.
8
Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.甲磺酸伊马替尼耐药的机制在 KIT 阳性转移性葡萄膜黑素瘤。
Clin Exp Metastasis. 2014 Jun;31(5):553-64. doi: 10.1007/s10585-014-9649-2. Epub 2014 Mar 21.
9
Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.一名慢性髓性白血病患者在接受甲磺酸伊马替尼治疗期间发生致命性乙型肝炎病毒再激活。
Leuk Lymphoma. 2006 Jan;47(1):155-7. doi: 10.1080/14639230500236818.
10
The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia.对于因Bcr/Abl诱导的白血病而接受甲磺酸伊马替尼治疗的小鼠，中枢神经系统是白血病细胞的一个庇护所。
Blood. 2003 Jun 15;101(12):5010-3. doi: 10.1182/blood-2002-10-3059. Epub 2003 Feb 20.

本文引用的文献

1
Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial.体重调整的中等剂量与固定剂量低分子肝素预防性抗凝对非重症和重症COVID-19患者静脉血栓栓塞的影响：COVI-DOSE试验，一项多中心、随机、开放标签的4期试验。
EClinicalMedicine. 2023 Jun;60:102031. doi: 10.1016/j.eclinm.2023.102031. Epub 2023 Jun 9.
2
Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial.静脉注射伊马替尼治疗 COVID-19 相关急性呼吸窘迫综合征的疗效和安全性：一项随机、双盲、安慰剂对照的临床试验。
Crit Care. 2023 Jun 8;27(1):226. doi: 10.1186/s13054-023-04516-4.
3
Baricitinib or imatinib in hospitalized COVID-19 patients: Results from COVINIB, an exploratory randomized clinical trial.巴瑞替尼或伊马替尼用于住院的新冠肺炎患者：探索性随机临床试验COVINIB的结果
J Med Virol. 2023 Feb;95(2):e28495. doi: 10.1002/jmv.28495.
4
Early antithrombotic therapy for another highly lethal viral pneumonia pandemic.针对另一场高致死性病毒性肺炎大流行的早期抗血栓治疗。
Clin Microbiol Infect. 2023 Mar;29(3):284-287. doi: 10.1016/j.cmi.2022.11.008. Epub 2022 Nov 19.
5
Long-term clinical outcomes of COVID-19 patients treated with imatinib.接受伊马替尼治疗的COVID-19患者的长期临床结局
Lancet Respir Med. 2022 Apr;10(4):e34-e35. doi: 10.1016/S2213-2600(22)00052-2. Epub 2022 Feb 17.
6
The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials.高强度抗凝治疗对 COVID-19 住院患者临床结局的影响：一项随机对照试验的荟萃分析。
J Infect Chemother. 2022 Feb;28(2):257-265. doi: 10.1016/j.jiac.2021.11.008. Epub 2021 Nov 17.
7
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial.治疗性肝素与预防性肝素对中症 COVID-19 住院患者的死亡、机械通气或入住重症监护病房的影响：RAPID 随机临床试验。
BMJ. 2021 Oct 14;375:n2400. doi: 10.1136/bmj.n2400.
8
Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.雾化肝素治疗急性呼吸窘迫综合征患者或有急性呼吸窘迫综合征风险患者的多中心、随机、双盲、安慰剂对照 3 期试验。
Lancet Respir Med. 2021 Apr;9(4):360-372. doi: 10.1016/S2213-2600(20)30470-7. Epub 2021 Jan 22.